SELK2 / Tetherex Pharma - LARVOL DELTA

A phase 2 study of SelK2 on sputum cell counts in COPD (ERS 2024) - P2 | "A single SelK2 dose significantly reduced absolute sputum neutrophils and eosinophils in COPD consistent with decreased migration from the blood. This study indicates potential for SelK2 as an anti-inflammatory COPD treatment. Table 1: Mean Sputum cells (x106/g) SelK2 (N=17) Placebo (N=8) p-value Screen Day 21 Screen Day 21 Neutrophils 4.1 1.7 5.8 5.8 0.041 Eosinophils 0.10 0.02 0.17 0.23 0.018"

P2 data • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) (clinicaltrials.gov) - P2 | N=61 | Completed | Sponsor: Tetherex Pharmaceuticals Corporation | Active, not recruiting ➔ Completed

Trial completion • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) (clinicaltrials.gov) - P2; N=61; Active, not recruiting; Sponsor: Tetherex Pharmaceuticals Corporation; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2021 ➔ Jan 2022; Trial primary completion date: Aug 2021 ➔ Dec 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Tetherex Pharmaceuticals Corporation; Trial completion date: Feb 2021 ➔ Sep 2021; Trial primary completion date: Jan 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Tetherex Pharmaceuticals Corporation

Clinical • New P2 trial • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (clinicaltrials.gov) - P2; N=207; Completed; Sponsor: Tetherex Pharmaceuticals Corporation; Active, not recruiting ➔ Completed; Trial completion date: Feb 2020 ➔ Nov 2019

Clinical • Trial completion • Trial completion date

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (clinicaltrials.gov) - P2; N=207; Active, not recruiting; Sponsor: Tetherex Pharmaceuticals Corporation; Trial primary completion date: Dec 2019 ➔ Oct 2019

Clinical • Trial primary completion date

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (clinicaltrials.gov) - P2; N=255; Recruiting; Sponsor: Tetherex Pharmaceuticals Corporation; N=190 ➔ 255

Clinical • Enrollment change

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (clinicaltrials.gov) - P2; N=190; Recruiting; Sponsor: Tetherex Pharmaceuticals Corporation; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (clinicaltrials.gov) - P2; N=190; Not yet recruiting; Sponsor: Tetherex Pharmaceuticals Corporation

Clinical • New P2 trial